Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
CAMBRIDGE, Mass., March 30, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the 16th Annual Needham Healthcare Conference in New York on Tuesday April 4, 2017 at 9:20 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Contacts Investors: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
